For relapsed and elderly acute myeloid leukemia patients, standard treatment is often not good enough. In this interview, Jorge Sierra, MD, PhD of the Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, discusses the alternative treatment options for these patients. Prof. Sierra highlights the importance of these patients being included in clinical trials and recommends alternative options if this is not a possibility. This interview was recorded at the International Conference on Acute Myeloid Leukemia 2017, Estoril, Portugal by the European School of Hematology (ESH).
What are the alternative treatment options for relapsed or elderly AML patients?
